{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:17:17Z","timestamp":1778883437116,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctro.2026.101138","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:16:17Z","timestamp":1771892177000},"page":"101138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"Andrea R.","family":"Filippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-6427","authenticated-orcid":false,"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-3628","authenticated-orcid":false,"given":"Vilde Drageset","family":"Haakensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francoise","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel M.","family":"Van Den Heuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Vercauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1904-1972","authenticated-orcid":false,"given":"Hans J.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratibha","family":"Chander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-7744","authenticated-orcid":false,"given":"Yao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolyon","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101138_b0005","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.3390\/cancers14225700","article-title":"The multidisciplinary approach in stage III non-small cell lung cancer over ten years: from radiation therapy optimisation to innovative systemic treatments","volume":"14","author":"Ferro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101138_b0010","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: an overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Current Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0015","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of Stage III NSCLC Guideline Expert Panel. Management of stage III non-small cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"42","author":"Daly","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0025","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.ctro.2026.101138_b0030","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.ctro.2026.101138_b0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0040","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110147","article-title":"Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer","volume":"194","author":"Smesseim","year":"2024","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.ctro.2026.101138_b0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-023-04212-5","article-title":"Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.ctro.2026.101138_b0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2024.100638","article-title":"Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC","volume":"5","author":"Vansteenkiste","year":"2024","journal-title":"JTO Clinical and Research Reports"},{"key":"10.1016\/j.ctro.2026.101138_b0075","article-title":"Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies","volume":"14","author":"Zhang","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.ctro.2026.101138_b0080","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.ctro.2026.101138_b0085","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.21037\/jtd-22-1604","article-title":"A real-world study of pneumonitis in non-small cell lung cancer patients receiving durvalumab following concurrent chemoradiation","volume":"15","author":"Akkad","year":"2023","journal-title":"Journal of Thoracic Disease"},{"key":"10.1016\/j.ctro.2026.101138_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctro.2026.101138_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0100","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semradonc.2014.11.002","article-title":"Intensity-modulated radiotherapy, not 3D conformal, is the preferred technique for treating locally advanced lung cancer","volume":"25","author":"Chang","year":"2014","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0110","article-title":"Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A Meta-Analysis","volume":"11","author":"Hu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ctro.2026.101138_b0115","article-title":"Modern radiotherapy technology: obstacles and opportunities to access in low- and middle-income countries","volume":"8","author":"Maitre","year":"2022","journal-title":"JCO Global Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5152\/balkanmedj.2014.14529","article-title":"Intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy strategies for locally advanced non-small-cell lung cancer","volume":"31","author":"Selek","year":"2014","journal-title":"Balkan Medical Journal"},{"key":"10.1016\/j.ctro.2026.101138_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.835844","article-title":"Impact of introducing intensity modulated radiotherapy on curative intent radiotherapy and survival for lung cancer","volume":"12","author":"Fornacon-Wood","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2024.01.217","article-title":"Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"119","author":"Han","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.ctro.2026.101138_b0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.radonc.2017.12.027","article-title":"Differences in lung injury after IMRT or proton therapy assessed by (18)FDG PET imaging","volume":"128","author":"Shusharina","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0140","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.prro.2016.01.015","article-title":"Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy","volume":"6","author":"Harder","year":"2016","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3857\/roj.2011.29.3.181","article-title":"Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer","volume":"29","author":"Kim","year":"2011","journal-title":"Radiation Oncology Journal"},{"key":"10.1016\/j.ctro.2026.101138_b0150","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.cllc.2023.08.007","article-title":"Developing a prediction model for radiation pneumonitis in lung cancer patients treated with stereotactic body radiation therapy combined with clinical, dosimetric factors, and laboratory biomarkers","volume":"24","author":"Huang","year":"2023","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.ctro.2026.101138_b0155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.11-1193","article-title":"Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy","volume":"141","author":"Takeda","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ctro.2026.101138_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2022.101130","article-title":"Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab","volume":"8","author":"Diamond","year":"2023","journal-title":"Advances in Radiation Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2022.06.003","article-title":"Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab","volume":"170","author":"Gao","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctro.2026.101138_b0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ctro.2020.05.006","article-title":"Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer","volume":"23","author":"Saito","year":"2020","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","article-title":"Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab","volume":"22","author":"Shintani","year":"2021","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.ctro.2026.101138_b0180","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","article-title":"Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a secondary analysis of a randomized clinical trial","volume":"10","author":"Chun","year":"2024","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/jjco\/hyad158","volume":"54","author":"Masuo","year":"2024","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1016\/j.ctro.2026.101138_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061162","article-title":"Patterns and incidence of pneumonitis and initial treatment outcomes with durvalumab consolidation therapy after radical chemoradiotherapy for stage III non-small cell lung cancer","volume":"16","author":"Sato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101138_b0195","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1634\/theoncologist.2016-0155","article-title":"Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy","volume":"21","author":"Wang","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctro.2026.101138_b0200","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1186\/s12885-023-11520-y","article-title":"Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2026.101138_b0205","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-8140(03)00119-1","article-title":"Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study","volume":"67","author":"Rancati","year":"2003","journal-title":"Radiotherapy and Oncology"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:47:37Z","timestamp":1778881657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"alternative-id":["S2405630826000339"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101138","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101138"}}